Tests IKS03 drug in adults with advanced B-cell non-Hodgkin lymphoma

Trial details

Who runs it

Iksuda Therapeutics Ltd.

Trial code

NCT05365659

Record updated

3 November 2026

Original description

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).Read full original descriptionShow less

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Inclusion: Males or females, ≥ 18 years of age; Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible; Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:; Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type); Follicular lymphoma (including duodenal-type follicular lymphoma); Mantle cell lymphoma; B cell lymphomas not specified; If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response; NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy; Must be in need of systemic treatment and not require immediate cytoreductive therapy; Part I: measurable or non-measurable disease; Part II: measurable disease according to The Revised Criteria/Lugano Classification; Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy; ECOG performance status 0 or 1; Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period; Ability to understand and give written informed consent.

Exclusion: Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding; Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement; Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks; Receipt of:; Any CD19-targeted therapy within 4 weeks; Any tumor vaccine within 6 weeks (must have progressed if previously received); Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after; Drugs known to impair renal function, including:; NSAIDS within 3 days; Aminoglycoside antibiotics, amphotericin B, etc. within 1 week; Bisphosphonates within 1 month; Prior solid organ transplant; Allogeneic HSCT within 6 months, or:; If receiving immunosuppression; If with active evidence of GVHD; Autologous hematopoietic stem cell transplantation (HSCT) within 3 months; Radiotherapy:; To target lesions within 4 weeks unless progression of the lesion has been documented; To non-target lesions within 1 week; Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks; Herbal therapies and supplements within 2 weeks; Strong inhibitors of cytochrome P450 within 2 weeks; Part 2: History of another malignancy within 2 years, with the exception of:; Treated, non-melanoma skin cancers; Treated carcinoma in situ (e.g., breast, cervix); Controlled, superficial carcinoma of the urinary bladder; T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits; Papillary thyroid carcinoma Stage I treated surgically for cure; Patients with:; Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable; Active uncontrolled bleeding or a known bleeding diathesis; Significant liver disease, including:; Non-infectious hepatitis; Hepatic cirrhosis (Child-Pugh Class B and Class C); Significant pulmonary disease or condition, including:; Significant symptomatic COPD, as assessed by the Investigator; History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis; History of pulmonary inflammatory disease, pneumonitis, ARDS; History of pneumonia within 1 month; Significant corneal disease or condition, including history of or current evidence of keratitis; Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months; Known HIV infection or AIDS; Active hepatitis B virus or hepatitis C virus infection; Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks; Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications; Known or suspected hypersensitivity to any of the excipients of formulated study drug; A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process; Drugs and Other Treatments to be Excluded:; Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks); Live/live-attenuated vaccines against infectious diseases within 4 weeks; Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):; Hemoglobin < 8.0 g/dL; Absolute neutrophil count < 1,000 per mm3; Platelet count < 75,000 per mm3; Any of the following laboratory abnormalities at baseline:; Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome; AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor; Estimated GFR ≤ 60 mL/min corrected for BSA; Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin; Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:; PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated); PTT > 1.5 × ULN; > 3× ULN if anticoagulated; Any of the following laboratory abnormalities at baseline aimed at assessing renal function:; Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA; Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin; Significant cardiovascular disease or condition, including:; Congestive heart failure or angina pectoris requiring therapy; Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia; Severe conduction disturbance (e.g., 3rd degree heart block); QTc interval ≥ 480 milliseconds; Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram; Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification; History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months; Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT); Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies); Patients documented to be CD19-negative; Any other investigational treatments within 3 weeks; Prophylactic use of hematopoietic growth factors within 1 week.

ClinicalTrials.gov NCT05365659